Alnylam Pharmaceuticals Aktie
276,50
EUR
-3,40
EUR
-1,21
%
322,65
USD
-4,58
USD
-1,40
%
Werbung
Alnylam Pharmaceuticals Aktie Analyse
| 30.03.17 | Alnylam Pharmaceuticals Neutral | UBS AG | |
| 24.11.09 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
| 26.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 25.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 15.09.08 | Alnylam Pharmaceuticals market weight | Thomas Weisel Partners LLC | |
| 21.08.08 | Alnylam Pharmaceuticals | Focus Money | |
| 10.10.07 | Alnylam Pharmaceuticals market perform | Piper Jaffray & Co. | |
| 14.08.07 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
|
Werbung
|
|||
Werbung
Werbung